Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Dermatology Urology Emergency Medicine Ophthalmology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Metabolic Syndrome

Part of Insulin Resistance

45 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Metabolic Syndrome

132 trials tracked for Metabolic Syndrome: 28 in phase 3 or 4 and 8 with published results. The most-cited published study has 43 citations.

132Trials tracked

28Phase 3 & 4

0Recruiting

8With published results

Phase distribution

Phase 4 18 Phase 3 10 Phase 2 31 Phase 1 4 Other / NA 69

Phase 3 Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies. Completed · 43 cited
Phase 4 Niacin, N-3 Fatty Acids and Insulin Resistance Completed · 42 cited
Phase 3 Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM) Completed · 40 cited
Phase 3 Exercise Dose and Metformin for Vascular Health in Metabolic Syndrome Completed · 32 cited
Phase 3 A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both Completed · 16 cited
Phase 3 The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome Completed · 12 cited

Show 44 more trials

Phase 4 Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir Completed · 9 cited
Phase 3 A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes Completed · 3 cited
Phase 4 Effect of Prolonged PDE-5 Inhibition on Insulin Signaling in Skeletal Muscle. Completed
Phase 4 Endogenous Opioid Activity and Affective State in Insulin Resistant Women Completed
Phase 4 Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome Completed
Phase 4 Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism Completed
Phase 4 Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome. Completed
Phase 4 Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome Completed
Phase 4 Simvastatin With or Without Ezetimibe and Atherothrombotic Biomarker Assessment Completed
Phase 4 The Effect of Fluvastatin XL® Treatment in Patients With Metabolic Syndrome Completed
Phase 4 Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance Completed
Phase 4 Effect of Aged Garlic Extract on Atherosclerosis Completed
Phase 4 Comparative Effect of Nebivolol vs. Metoprolol on Insulin Sensitivity and Fibrinolytic Balance in Metabolic Syndrome Completed
Phase 4 Mechanisms Underlying Metabolic Syndrome in Obesity Completed
Phase 4 Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome Completed
Phase 4 The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study Completed
Phase 4 Effect of Crestor (Rosuvastatin) on Lipid Levels in Patients With Metabolic Syndrome Completed
Phase 4 Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome Completed
Phase 3 A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes Completed
Phase 3 An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia Completed
Phase 3 Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia Completed
Phase 3 Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED) Completed
Phase 2 Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults Completed
Phase 2 Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency Completed
Phase 2 Oral Nitrite in Adults With Metabolic Syndrome and Hypertension Completed
Phase 2 Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome Completed
Phase 2 Prothrombotic Inflammatory Markers in Women With Metabolic Syndrome - Effect of Atorvastatin Completed
Phase 2 Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome Completed
Phase 2 Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes Completed
Phase 2 Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases Completed
Phase 2 Effect of Fucoxanthin on the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion Completed
Phase 2 Metformin in Kidney Disease Completed
Phase 2 Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome Completed
Phase 2 Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome Completed
Phase 2 Effects of Leptin Replacement in Children Completed
Phase 2 Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL Completed
Phase 2 Safety and Efficacy Study of ISIS 301012 (Mipomersen) Administration in High Risk Statin Intolerant Subjects Completed
Phase 2 A Study of LY3561774 in Participants With Mixed Dyslipidemia Completed
Phase 2 Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes Completed
Phase 2 T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin Completed
Phase 2 Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration Completed
Phase 2 Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction Completed
Phase 2 Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia Completed
Phase 2 Islet Allotransplantation With Steroid Free Immunosuppression Completed

Showing the 50 most-cited and recently-updated of 132 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

‹ Prev 1 2 3 4 Next ›

Questions about Metabolic Syndrome

Can changing my diet fix gut-liver problems causing metabolic disorders?

Changing your diet can help fix gut-liver problems that cause metabolic disorders by reducing inflammation and improving how your liver processes nutrients.

Full answer →

How do probiotics help regulate fat cells in metabolic disorders?

Probiotics and postbiotics help regulate fat cells by reducing inflammation, lowering food intake, and changing how the body absorbs fats and sugars.

Full answer →

Does eating processed meat increase my risk of metabolic disorders?

Eating processed meat is linked to a higher risk of metabolic disorders, including heart disease, diabetes, and fatty liver, according to multiple reviews.

Full answer →

What are the main risk factors for Metabolic Syndrome in men?

In men, main risk factors for metabolic syndrome include abdominal obesity, high blood sugar, high triglycerides, low HDL cholesterol, high blood pressure, alcohol drinking, and a diet high in ultra-processed foods.

Full answer →

Can Tai Chi and aerobic exercise help lower Metabolic Syndrome risk factors?

Yes, both Tai Chi and aerobic exercise can help lower several Metabolic Syndrome risk factors, including blood pressure, waist circumference, and cholesterol.

Full answer →

See all 5 questions about Metabolic Syndrome →